The phenomenon of weight loss in patients with chronic heart failure
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Main Article Content
Abstract
A characteristic sign of chronic heart failure (CHF) is a high frequency of comorbid conditions, one of which is the phenomenon of weight loss. Cardiac cachexia is a systemic metabolic disorder characterized by an unintentional decrease in body weight due to loss of all body components, namely, skeletal muscle, adipose tissue and bone tissue, and identified as a marker of nutritional status, has prognostic value in patients with CHF, regardless of age, NYHA class, left ventricular ejection fraction, and peak oxygen consumption. The article discusses the prevalence, criteria, prognostic significance of cardiac cachexia, as well as immune, metabolic and neurohormonal pathogenetic mechanisms that lead to anabolic-catabolic imbalance and contribute to the progression of CHF. Given the methodological difficulties of proper assessment of unintentional body weight loss over a certain previous period of outpatient follow-up in patients with CHF, it becomes urgent to determine the objective («static») characteristics of the nutritional status of patients, which are associated with an unfavorable clinical prognosis. The article demonstrates the results of our own research to determine prognostic factors based on indicators of the nutritional status of patients the clinical significance of the loss of individual body components is highlighted, preventive and therapeutic approaches to influence body weight loss in patients with CHF are described – nutritional support, neurohormonal blockade, the effect on the intestinal microflora, correction of anemia and iron deficiency, the use of appetite stimulants, immunomodulatory agents, anabolic hormones and physical training.
Article Details
Keywords:
References
Арутюнов Г.П., Серов Р.А. Морфофункциональные изменения тонкой кишки и поперечно-полосатой мускулатуры у больных с хронической сердечной недостаточностью // Сердечная недостаточность.– 2001.– Vol. 2.– С. 127–131.
Войцеховська К.В., Воронков Л.Г., Федьків С.В. та ін. Клінічний прогноз упродовж 12 місяців та його предиктори в пацієнтів з хронічною серцевою недостатністю та зниженою фракцією викиду лівого шлуночка // Укр. кардіол. журн.– 2019.– № 6.– С. 53–64. doi: https://doi.org/10.31928/1608-635X-2019.6.5364.
Воронков Л.Г., Войцеховська К.В., Федьків С.В. та ін. Предиктори довгострокового клінічного прогнозу в пацієнтів з хронічною серцевою недостатністю та зниженою фракцією викиду лівого шлуночка // Укр. кардіол. журн.– 2019.– № 5.– С. 33–43. doi: https://doi.org/10.31928/10.31928/1608-635X-2019.5.3342.
Ефремова Е.В., Шутов А.М., Бородулина Е.О. Проблема коморбидности при хронической сердечной недостаточности // Ульян. медико-биол. журн.– 2015.– № 4.– С. 47–53.
Надаль-Гинард К. Когда одно мешает другому – коморбидность на злобе дня // Новая медицина тысячелетия.– 2012.– № 6.– С. 22–24.
Обрезан А.Г., Куликов Н.В. Нейрогуморальный дисбаланс при хронической сердечной недостаточности: классические и современные позиции // Рос. кардиол. журн.– 2017.– № 9 (149).– С. 83–92. doi: https://doi.org/10.15829/1560-4071-2017-9-83-92.
Alves C.R., da Cunha T.F., da Paixão N.A. Brum P.C. Aerobic exercise training as therapy for cardiac and cancer cachexia // Life Sci.– 2015.– Vol. 125.– P. 9–14. doi: https://doi.org/10.1016/j.lfs.2014.11.029.
Anker S.D., Chua T.P., Ponikowski P. et al. Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia // Circulation.– 1997.– Vol. 96.– P. 526–534. doi: https://doi.org/10.1161/01.CIR.96.2.526.
Anker S.D., Negassa A., Coats A.J. et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensinconverting-enzyme inhibitors: an observational study // Lancet.– 2003.– Vol. 361.– P. 1077–1083. doi: https://doi.org/10.1016/S0140-6736(03)12892-9.
Anker S.D., Ponikowski P., Varney S. et al. Wasting as independent risk factor for mortality in chronic heart failure // Lancet.– 1997.– Vol. 349 (9058).– P. 1050–1053. doi: https://doi.org/10.1016/S0140-6736(96)07015-8.
Aquilani R., Opasich C., Verri M. et al. Is nutritional intake adequate in chronic heart failure patients? // J. Am. Coll. Cardiol.– 2003.– Vol. 42 (7).– P. 1218–1223. doi: https://doi.org/10.1016/s0735-1097(03)00946-x.
Bahls M., Felix S.B. Cachexia and right ventricular dysfunction in chronic heart failure: what is the chicken and what the egg? // Eur. Heart J.– 2016.– Vol. 37 (21).– P. 1692–1694. doi: https://doi.org/10.1093/eurheartj/ehw118.
Barclay R.D., Burd N.A., Tyler C. et al. The Role of the IGF-1 Signaling Cascade in Muscle Protein Synthesis and Anabolic Resistance in Aging Skeletal Muscle // Front. Nutr.– 2019. doi: https://doi.org/10.3389/fnut.2019.00146.
Bei Y., Xiao J. MicroRNAs in muscle wasting and cachexia induced by heart failure // Nat. Rev. Cardiol.– 2017.– Vol. 14 (9).– P. 566. doi: https://doi.org/10.1038/nrcardio.2017.122.
Burton L.A., Mcmurdo M.E., Struthers A.D. Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people? // Clin. Endocrinol. (Oxf).– 2011.– Vol. 75.– P. 725–729. doi: https://doi.org/10.1111/j.1365-2265.2011.04148.x.
Caminiti G., Volterrani M., Iellamo F. et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study // J. Am. Coll. Cardiol.– 2009.– Vol. 54 (10).– P. 919–927. doi: https://doi.org/10.1016/j.jacc.2009.04.078.
Carson M., Reid J., Hill L. et al. The need for a specific definition of cardiac cachexia // Eur. J. Cardiovasc. Nursing.– 2019.– Vol. 1–2. doi: https://doi.org/10.1177/1474515119866686.
Cicoira M., Maggioni A.P., Latini R. et al. Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Faolure Trial // Eur. J. Heart Failure.– 2007.– Vol. 9 (4).– P. 397–402. doi: https://doi.org/10.1016/j.ejheart.2006.10.016.
Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // New Engl. J. Med.– 2001.– Vol. 345.– P. 1667–1675. doi: https://doi.org/10.1056/NEJMoa010713.
De Boer M.D. Ghrelin and cachexia: Will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes? // Mol. Cell. Endocrinol.– 2011.– Vol. 340 (1).– P. 97–105. doi: https://doi.org/10.1016/j.mce.2011.02.012.
Donohoe С.L., Ryan A.M., Reynolds J.V. Cancer Cachexia: mechanisms and clinical implications // Gastroenterol. Res. Prac.– 2011.– Vol. 2011.– P. 601434. doi: https://doi.org/10.1155/2011/601434.
Ebner N., Springer J., Kalantar-Zadehb K. et al. Mechanism and novel therapeutic approaches to wasting in chronic disease // Maturitas.– 2013.– Vol. 75 (3).– P. 199–206. doi: https://doi.org/10.1016/j.maturitas.2013.03.014.
El Desoky E.S. Drug therapy of heart failure: an immunologic view // Am. J. Ther.– 2011.– Vol. 18 (5).– P. 416–425. doi: https://doi.org/10.1097/MJT.0b013e3181d169db.
Evans W.J., Morley J.E., Argiles J. et al. Cachexia: a new definition // Clin. Nutr.– 2008.– Vol. 27.– P. 793–799. doi: https://doi.org/10.1016/j.clnu.2008.06.013.
Fildes J.E., Shaw S.M., Yonan N., Williams S.G. The immune system and chronic heart failure: is the heart in control? // J. Am. Coll. Cardiol. 2009.– Vol. 53 (12).– P. 1013–1020. doi: https://doi.org/10.1016/j.jacc.2008.11.046.
Flynn K.E., Pina I.L., Whellan D.J. et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial // JAMA.– 2009.– Vol. 301 (14).– P. 1451–1459. doi: https://doi.org/10.1001/jama.2009.457.
Fülster S., Tacke M., Sandek A. et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF) // Eur. Heart J.– 2013.– Vol. 34.– P. 512–519. doi: https://doi.org/10.1093/eurheartj/ehs381.
Gomes M.J., Martinez P.F., Campos D.H. et al. Beneficial effects of physical exercise on functional capacity and skeletal muscle oxidative stress in rats with aortic stenosis-induced heart failure // Oxid. Med. Cell. Longev.– 2016.– Vol. 2016.– P. 8695716–8695716. doi: https://doi.org/10.1155/2016/8695716.
Grech A., Breck J., Heidelbaugh J. Adverse effects of testosterone replacement therapy: an update on the vidence and controversy // Ther. Adv. Drug. Saf.– 2014.– Vol. 5 (5).– P. 190–200. doi: https://doi.org/10.1177/2042098614548680.
Gulati K., Guhathakurta S., Joshi J. et al. Cytokines and their Role in Health and Disease: A Brief Overview // MOJ. Immunol.– 2016.– Vol. 4 (2).– P. 00121. doi: https://doi.org/10.15406/moji.2016.04.00121.
Heymsfield S.B., Casper K. Congestive heart failure: clinical management by use of continuous nasoenteric feeding // Am. J. Clin. Nutr.– 1989.– Vol. 50 (3).– P. 539–544. doi: https://doi.org/10.1093/ajcn/50.3.539.
Iellamo F., Volterrani M., Caminiti G. et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study // J. Am. Coll. Cardiol.– 2010.– Vol. 56 (16).– P. 1310–1316. doi: https://doi.org/10.1016/j.jacc.2010.03.090.
Jocken J.W., Blaak E. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity // Physiology & Behavior.– 2008.– Vol. 94 (2).– P. 219–230. doi: https://doi.org/10.1016/j.physbeh.2008.01.002.
Josiak K., Jankowska E.A., Piepoli M.F. et al. Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones // J. Cachexia Sarcopenia Muscle.– 2014.– Vol. 5 (4).– P. 287–296. doi: https://doi.org/10.1007/s13539-014-0152-z.
Kamiya K., Hamazaki N., Matsuzawa R. et al. Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease // J. Cachexia. Sarcopenia and Muscle Clinical Reports.– 2017.– Vol. 2 (2).– P. 13. doi: https://doi.org/10.17987/jcsm-cr.v2i2.41.
King D., Smith M.L., Chapman T.J. et al. Fat malabsorption in elderly patients with cardiac cachexia // Age Ageing.– 1996.– Vol. 25.– P. 144–149. doi: https://doi.org/10.1093/ageing/25.2.144.
Lainscak M., Keber I., Anker S.D. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study // Int. J. Cardiol.– 2006.– Vol. 106.– P. 319–322. doi: https://doi.org/10.1016/j.ijcard.2005.01.061.
Lima A.R., Martinez P.F., Okoshi K. et al. Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure // Int. J. Exp. Path.– 2010.– Vol. 91 (1).– P. 54–62. doi: https://doi.org/10.1111/j.1365-2613.2009.00683.x.
Lin J., Arnold H.B., Della-Fera M.A. et al. Myostatin knockout in mice increases myogenesis and decreases adipogenesis // Biochem. Biophys. Res. Commun.– 2002.– Vol. 291.– P. 701–706. doi: https://doi.org/10.1006/bbrc.2002.6500.
Lippi G., Sanchis-Gomar F. Global epidemiology and future trends of heart failure // AME Med. J.– 2020.– Vol. 5.– P. 15. doi: https://doi.org/10.21037/amj.2020.03.03.
Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) // Circulation.– 2004.– Vol. 109 (13).– P. 1594–1602. doi: https://doi.org/10.1161/01.CIR.0000124490.27666.B2.
Martinez P.F., Bonomo C., Guizoni D.M. et al. Influence of N-acetylcysteine on oxidative stress in slow-twitch soleus muscle of heart failure rats // Cell. Physiol. Biochem.– 2015.– Vol. 35 (1).– P. 148–159. doi: https://doi.org/10.1159/000369683.
Masayuki Y., Takayoshi T., Chiho K. et al. Serum Cortisol as a Useful Predictor of Cardiac Events in Patients With Chronic Heart Failure The Impact of Oxidative Stress // Circ. Heart Fail.– 2009.– Vol. 2.– P. 608–615. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.109.868513.
McMurray J.J.V., Adamopoulos S., Anker S.D. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 // Eur. Heart J.– 2012.– Vol. 33 (14).– P. 1787–1847. doi: https://doi.org/10.1093/eurheartj/ehs104.
Melenovsky V., Kotrc M., Borlaug B.A. et al. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure // J. Am. Coll. Cardiol.– 2013.– Vol. 62.– P. 1660–1670. doi: https://doi.org/10.1016/j.jacc.2013.06.046.
Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of ubiquitin-proteasome pathway // New Engl. J. Med.– 1996.– Vol. 335.– P. 1897–1905. doi: https://doi.org/10.1056/NEJM199612193352507.
Moludi J., Maleki V., Jafari-Vayghyan H. Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics // Clin. Experim. Pharmacol. Physiol.– 2020.– Vol. 47 (6).– P. 927–939. doi: https://doi.org/10.1111/1440-1681.13250.
Morley J.E., von Haehling S., Anker S.D. Are we closer to having drugs to treat muscle wasting disease? // J. Cachexia Sarcopenia Muscle.– 2014.– Vol. 5.– P. 83–87. doi: https://doi.org/10.1007/s13539-014-0149-7.
Müller T.D., Nogueiras R., Andermann M.L. et al. Ghrelin. Mol Metab.– 2015.– Vol. 4.– P. 437–460. doi: https://doi.org/10.1016/j.molmet.2015.03.005.
Negrao C.E., Middlekauff H.R., Gomes-Santos I.L., Antunes-Correa L.M. Effects of exercise training on neurovascular control and skeletal myopathy in systolic heart failure // Am. J. Physiol. Heart Circ. Physiol.– 2015.– Vol. 308 (8).– P. H792–H802. doi: https://doi.org/10.1152/ajpheart.00830.2014.
Niebauer J., Volk H., Kemp M. et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study // Lancet.– 1999.– Vol. 353.– P. 1838–1842. doi: https://doi.org/10.1016/S0140-6736(98)09286-1.
Okoshi M.P., Capalbo R.V., Romeiro F.G., Okoshi K. Cardiac Cachexia: Perspectives for Prevention and Treatment // Arq. Bras. Cardiol.– 2017.– Vol. 108 (1).– P. 74–80. doi: https://doi.org/10.5935/abc.20160142.
Onder G., Liperoti R., Russo A. et al. Body mass index, free insulin-like growth factor I, and physical function among older adults: Results from the ilSIRENTE study // Am. J. Physiol. Endocrinol. Metab.– 2006.– Vol. 291.–P. E829–E834. doi: https://doi.org/10.1152/ajpendo.00138.2006.
Oreopoulos A., Padwal R., Kalantar-Zadeh K. et al. Body mass index and mortality in heart failure: a metaanalysis // Am. Heart J.– 2008.– Vol. 156 (1).– P. 13–22. doi: https://doi.org/10.1016/j.ahj.2008.02.014.
Packer M. et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure // New Engl. J. Med.– 2001.– Vol. 344.– P. 1651–1658. doi: https://doi.org/10.1056/NEJM200105313442201.
Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on survival in severe chronic heart failure // New Engl. J. Med.– 2001.– Vol. 344.– P. 1651–1658. doi: https://doi.org/10.1056/NEJM200105313442201.
Piepoli M.F., Conraads V., Corrà U. et al. Exercise training in heart failure: from theory to practice. A consensus document of the heart failure association and the european association for cardiovascular prevention and rehabilitation // Eur. J. Heart Fail.– 2011.– Vol. 13.– P. 347–357. doi: https://doi.org/10.1093/eurjhf/hfr017.
Pocock S.J., McMurray J.J., Dobson J. et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme // Eur. Heart J.– 2008.– Vol. 29.– P. 2641–2650. doi: https://doi.org/10.1093/eurheartj/ehn420.
Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. J. Heart Fail.– 2016.– Vol. 18 (8).– P. 891–975. doi: https://doi.org/10.1002/ejhf.592.
Ramalingam L., Menikdiwela K., LeMieux M. et al. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance // Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease.– 2017.– Vol. 1863 (5).– P. 1106–1114. doi: https://doi.org/10.1016/j.bbadis.2016.07.019.
Redza-Dutordoir M., Averill-Bates D.A. Activation of apoptosis signalling pathways by reactive oxygen species. Biochimica et Biophysica Acta (BBA) // Molecular Cell Research.– 2016.– Vol. 1863 (12).– P. 2977–2992. doi: https://doi.org/10.1016/j.bbamcr.2016.09.012.
Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure // Eur. Heart J.– 2001.– Vol. 22 (17).– P. 1527–1560. doi: https://doi.org/10.1053/euhj.2001.2783.
Riehle C., Abel E.D. Insulin Signaling and Heart Failure // Circulation Research.– 2016.– Vol. 118.– P. 1151–1169. doi: https://doi.org/10.1161/CIRCRESAHA.116.306206.
Rozentryt P., von Haehling S., Lainscak M. et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers a randomized, double-blind pilot study // J. Cachexia. Sarcopenia Muscle.– 2010.– Vol. 1 (1).– P. 35–42. doi: https://doi.org/10.1007/s13539-010-0008-0.
Sandek A., Bauditz J., Swidsinski A. et al. Altered Intestinal Function in Patients With Chronic Heart Failure // J. Amer. Coll. Cardiology.– 2007.– Vol. 50 (16).– P. 1561–1569. doi: https://doi.org/10.1016/j.jacc.2007.07.016.
Sandek A., Bauditz J., Swidsinski A. et al. Altered intestinal function in patients with chronic heart failure // J. Am. Coll. Cardiol.– 2007.– Vol. 50.– P. 1561–1569. doi: https://doi.org/10.1016/j.jacc.2007.07.016.
Shaw S.M., Shah M.K., Williams S.G., Fildes J.E. Immunological mechanisms of pentoxifylline in chronic heart failure // Eur. J. Heart Fail.– 2009.– Vol. 11 (2).– P. 113–118. doi: https://doi.org/10.1093/eurjhf/hfn040.
Song Y.–H., Li Y., Du J. et al. Muscle-specific expression of IGF-1 blocks angiotensin-II-induced skeletal muscle wasting // J. Clin. Invest.– 2005.– Vol. 115.– P. 451–458. doi: https://doi.org/10.1172/JCI22324.
Souza R.W., Piedade W.P., Soares L.C. et al. Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions // PLoS One.– 2014.– Vol. 9 (10).– P. e110020. doi: https://doi.org/10.1371/journal.pone.0110020.
Springer J., von Haehling S. ACE Inhibitors and Sarcopenia: Covering All the BASEs? // Drugs. Aging.– 2016.– Vol. 33.– P. 839–840. doi: https://doi.org/10.1007/s40266-016-0417-7.
Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial // Lancet.– 2008.– Vol. 372.– P. 1223–1230. doi: https://doi.org/10.1016/S0140-6736(08)61239-8.
Tenover J.S. Effects of testosterone supplementation in the aging male // J. Clin. Endocrinol. Metab.– 1992.– Vol. 75 (4).– P. 1092–1098. doi: https://doi.org/10.1210/jcem.75.4.1400877.
Urschel K., Cicha I. TNF-α in the cardiovascular system: from physiology to therapy // Intern. J. Interferon.– 2015.– Vol. 7.– P. 9–25. doi: https://doi.org/10.2147/IJICMR.S64894.
Van Linthout S., Tschöpe C. Inflammation – cause or consequence of heart failure or both? // Curr. Heart Fail. Rep.– 2017.– Vol. 14.– P. 251–265. doi: https://doi.org/10.1007/s11897-017-0337-9.
Von H.S., Anker S.D. Cachexia as a major underestimated and unmet medical need: facts and numbers // J. Cachex. Sarcopenia. Muscle.– 2010.– Vol. 1.– P. 1–5. doi: https://doi.org/10.1007/s13539-010-0002-6.
Von Haehling S., Garfias Macedo T., Valentova M. et al. Muscle wasting as an independent predictor of survival in patients with chronic heart failure // J. Cachexia Sarcopenia and Muscle.– 2020. doi: https://doi.org/10.1002/jcsm.12603.
Von Haehling S., Anker S.D. Treatment of cachexia: an overview of recent developments // Int. J. Cardiol.– 2015.– Vol. 184.– P. 736–742. doi:https://doi.org/10.1016/j.jamda.2014.09.007.
Zamora E., Díez-López C., Josep Lupón J. et al. Weight Loss in Obese Patients With Heart Failure // J. Amer. Heart Association.– 2016.– Vol. 5. doi: https://doi.org/10.1161/JAHA.115.002468.
Zhao Q., Li J., Yang J., Li R. Association of total cholesterol and HDL-C levels and outcome in coronary heart disease patients with heart failure. Medicine (Baltimore).– 2017.– Vol. 96 (9).– P. e6094. doi: https://doi.org/10.1097/MD.0000000000006094.